MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full
Receipt of FDA Warning Letter for AXIOFILL Classification; Not Related to Safety Request for Designation for AXIOFILL Submitted to FDA and Currently...
United States Matt Notarianni Josephh Capper Public Health Service Mimedx Group Inc Drug Administration
Source: globenewswire.com